Pamela Samson1, Aalok Patel1, Cliff G Robinson2, Daniel Morgensztern3, Su-Hsin Chang4, Graham A Colditz4, Saiama Waqar3, Traves D Crabtree1, A Sasha Krupnick1, Daniel Kreisel1, G Alexander Patterson1, Bryan F Meyers1, Varun Puri5. 1. Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St. Louis, Missouri. 2. Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri. 3. Division of Medical Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri. 4. Division of Public Health Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri. 5. Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St. Louis, Missouri. Electronic address: puriv@wudosis.wustl.edu.
Abstract
BACKGROUND: This study evaluated the cost-effectiveness of combination chemotherapy, radiotherapy, and surgical intervention (CRS) vs definitive chemotherapy and radiotherapy (CR) in clinical stage IIIA non-small cell lung cancer (NSCLC) patients at academic and nonacademic centers. METHODS: Patients with clinical stage IIIA NSCLC receiving CR or CRS from 1998 to 2010 were identified in the National Cancer Data Base. Propensity score matching on patient, tumor, and treatment characteristics was performed. Medicare allowable charges were used for treatment costs. The incremental cost-effectiveness ratio (ICER) was based on probabilistic 5-year survival and calculated as cost per life-year gained. RESULTS: We identified 5,265 CR and CRS matched patient pairs. Surgical resection imparted an increased effectiveness of 0.83 life-years, with an ICER of $17,618. Among nonacademic centers, 1,634 matched CR and CRS patients demonstrated a benefit with surgical resection of 0.86 life-years gained, for an ICER of $17,124. At academic centers, 3,201 matched CR and CRS patients had increased survival of 0.81 life-years with surgical resection, for an ICER of $18,144. Finally, 3,713 CRS patients were matched between academic and nonacademic centers. Academic center surgical patients had an increased effectiveness of 1.5 months gained and dominated the model with lower surgical cost estimates associated with lower 30-day mortality rates. CONCLUSIONS: In stage IIIA NSCLC, the selective addition of surgical resection to CR is cost-effective compared with definitive chemoradiation therapy at nonacademic and academic centers. These conclusions are valid over a range of clinically meaningful variations in cost and treatment outcomes.
BACKGROUND: This study evaluated the cost-effectiveness of combination chemotherapy, radiotherapy, and surgical intervention (CRS) vs definitive chemotherapy and radiotherapy (CR) in clinical stage IIIA non-small cell lung cancer (NSCLC) patients at academic and nonacademic centers. METHODS:Patients with clinical stage IIIA NSCLC receiving CR or CRS from 1998 to 2010 were identified in the National Cancer Data Base. Propensity score matching on patient, tumor, and treatment characteristics was performed. Medicare allowable charges were used for treatment costs. The incremental cost-effectiveness ratio (ICER) was based on probabilistic 5-year survival and calculated as cost per life-year gained. RESULTS: We identified 5,265 CR and CRS matched patient pairs. Surgical resection imparted an increased effectiveness of 0.83 life-years, with an ICER of $17,618. Among nonacademic centers, 1,634 matched CR and CRSpatients demonstrated a benefit with surgical resection of 0.86 life-years gained, for an ICER of $17,124. At academic centers, 3,201 matched CR and CRSpatients had increased survival of 0.81 life-years with surgical resection, for an ICER of $18,144. Finally, 3,713 CRSpatients were matched between academic and nonacademic centers. Academic center surgical patients had an increased effectiveness of 1.5 months gained and dominated the model with lower surgical cost estimates associated with lower 30-day mortality rates. CONCLUSIONS: In stage IIIA NSCLC, the selective addition of surgical resection to CR is cost-effective compared with definitive chemoradiation therapy at nonacademic and academic centers. These conclusions are valid over a range of clinically meaningful variations in cost and treatment outcomes.
Authors: Varun Puri; Traves D Crabtree; Steven Kymes; Martin Gregory; Jennifer Bell; Jeffrey D Bradley; Clifford Robinson; G Alexander Patterson; Daniel Kreisel; Alexander S Krupnick; Bryan F Meyers Journal: J Thorac Cardiovasc Surg Date: 2011-12-09 Impact factor: 5.209
Authors: David W Johnstone; Roger W Byhardt; David Ettinger; Charles B Scott Journal: Int J Radiat Oncol Biol Phys Date: 2002-10-01 Impact factor: 7.038
Authors: Michael E Stokes; Catherine E Muehlenbein; Martin D Marciniak; Douglas E Faries; Saeed Motabar; Theresa W Gillespie; Joseph Lipscomb; Kevin B Knopf; Don P Buesching Journal: J Manag Care Pharm Date: 2009-10
Authors: Hale B Caglar; Elizabeth H Baldini; Megan Othus; Michael S Rabin; Raphael Bueno; David J Sugarbaker; Steven J Mentzer; Pasi A Jänne; Bruce E Johnson; Aaron M Allen Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Jiayi Huang; Pamela Samson; Stephanie M Perkins; George Ansstas; Milan G Chheda; Todd A DeWees; Christina I Tsien; Clifford G Robinson; Jian L Campian Journal: J Neurooncol Date: 2016-11-14 Impact factor: 4.130
Authors: Stacyann Bailey; Qian Wang; Chung Yin Kong; Kimberly Stone; Rajwanth Veluswamy; Susan E Bates; Cardinale B Smith; Juan P Wisnivesky; Keith Sigel Journal: Curr Probl Cancer Date: 2022-05-21 Impact factor: 2.367
Authors: Elizabeth A David; Robert J Canter; Yingjia Chen; David T Cooke; Rosemary D Cress Journal: Ann Thorac Surg Date: 2016-06-09 Impact factor: 4.330
Authors: Andrew Tang; Andrew Feczko; Sudish C Murthy; Siva Raja; Alejandro Bribriesco; Dean Schraufnagel; Usman Ahmad; Daniel P Raymond; Monisha Sudarshan Journal: JTCVS Open Date: 2022-02-23